Clinical Trials Browser

NIH × Interventional × Tamoxifen × Clear all

NCT01272037 2026-06-03

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Phase 3 Active not recruiting

5,018 enrolled 14 charts

Carcinoma, Intraductal, Noninfiltrating

NCT00310180 2026-05-29

TAILORx

Phase 3 Active not recruiting

10,273 enrolled 14 charts

Breast Neoplasms

NCT02311933 2026-05-29

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Phase 2 Active not recruiting

81 enrolled 9 charts

Breast Neoplasms

NCT06195306 2026-05-20

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT05941520 2026-05-13

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT06184750 2026-05-13

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Phase 2 Recruiting

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT02101788 2025-11-13

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Phase 2/3 Completed

260 enrolled 20 charts

Cystadenocarcinoma, Serous

NCT00601900 2025-05-23

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

Phase 3 Completed

394 enrolled 11 charts

Breast Neoplasms

NCT00005970 2020-08-14

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00041080 2019-07-30

Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Phase 3 Completed

139 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

NCT00729586 2019-07-23

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Phase 2 Completed

73 enrolled 13 charts

Endometrial Neoplasms

NCT00118157 2017-12-04

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Phase 2 Completed

19 enrolled 6 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00590785 2017-08-25

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Phase 3 Completed

Breast Neoplasms

NCT00108069 2015-11-05

Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors

Phase 2 Completed

43 enrolled 11 charts

Brain Neoplasms, Glioma, Neoplasms, Disease Progression

NCT00119262 2014-05-15

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Phase 2 Completed

226 enrolled 8 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT00489944 2014-01-10

Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma

Phase 2 Unknown

Uveal Melanoma

NCT00492505 2014-01-10

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

Phase 2 Unknown

Melanoma

NCT00492687 2014-01-10

Radiation Therapy, Temozolomide, Tamoxifen, and Carboplatin in Treating Patients With Malignant Gliomas

Phase 2 Unknown

Astrocytoma, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT00003418 2013-12-19

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00003678 2013-12-19

Tamoxifen in Treating Women With Breast Cancer

Phase 3 Unknown

20,000 enrolled

Breast Neoplasms

NCT00010140 2013-12-18

Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00002579 2013-11-06

Tamoxifen Following Combination Chemotherapy in Treating Women With Operable Invasive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002580 2013-11-06

Tamoxifen, Ovarian Ablation, and/or Combination Chemotherapy in Treating Premenopausal Women With Stage I, Stage II, or Stage IIIA Invasive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002581 2013-11-06

Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002755 2013-11-06

Standard Chemotherapy Compared With High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00003679 2013-11-06

Combination Chemotherapy in Treating Women With Breast Cancer

Phase 3 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00003680 2013-11-06

Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer

Phase 3 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00126464 2013-11-06

Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast

Phase NA Unknown

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT00002720 2013-09-20

Surgery With or Without Lymph Node Removal in Treating Older Women With Stage I Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00003013 2013-09-17

Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00305838 2013-08-12

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00002460 2013-08-07

Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00006030 2013-08-07

Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00024336 2013-08-07

Radiation Therapy and Tamoxifen in Treating Children With Newly Diagnosed Brain Stem Glioma

Phase 2 Unknown

Central Nervous System Neoplasms

NCT00629278 2013-08-07

Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer

Phase 3 Unknown

Breast Neoplasms

NCT00002582 2013-08-02

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00032136 2013-08-02

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00002608 2013-07-10

Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Phase 2 Completed

CNSEndocrineGastrointestinalHead & NeckOther solid neoplasmSarcomaThoracic

Familial ependymoma, Thyroid Cancer, Papillary, Mesothelioma, Malignant, Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Medulloblastoma, Oligodendroglioma, Pheochromocytoma, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Adenocarcinoma, Follicular, Adrenocortical Carcinoma, Carcinoma, Medullary, Glioma, Subependymal, Gliosarcoma, Optic Nerve Glioma, Thyroid Carcinoma, Anaplastic

NCT00003424 2013-06-26

Tamoxifen in Treating Patients With Primary Liver Cancer

Phase 3 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT00002967 2013-06-21

Octreotide, Tamoxifen, and Chemotherapy in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms, Carcinoma, Ductal, Breast

NCT00052728 2013-06-19

Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT00003992 2013-06-03

Chemotherapy Plus Monoclonal Antibody Therapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Overexpresses HER2

Phase 2 Completed

Breast Neoplasms

NCT00047099 2013-05-30

Combination Chemotherapy in Treating Women With Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00005908 2013-03-19

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

Phase 2 Completed

30 enrolled 12 charts

Breast Neoplasms

NCT00016276 2013-01-16

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

Phase 3 Terminated

Breast Neoplasms, Inflammatory Breast Neoplasms, Cardiotoxicity

NCT00002646 2012-01-05

Hormone Therapy in Treating Postmenopausal Women With Receptor-Positive Breast Cancer

Phase 3 Completed

Breast Neoplasms

NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Phase 2 Unknown

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT00003016 2009-02-09

Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer

Phase 3 Unknown

20,000 enrolled

Breast Neoplasms

NCT00033683 2009-02-09

Combination Chemotherapy in Treating Women With Resected Breast Cancer

Phase 2 Unknown

Breast Neoplasms

NCT00077168 2009-02-09

Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole

Phase 2 Unknown

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating